| The spread and evolution of rabies virus: conquering new frontiers CR Fisher, DG Streicker, MJ Schnell Nature Reviews Microbiology 16 (4), 241-255, 2018 | 272 | 2018 |
| Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles DF Tucker, JT Sullivan, KA Mattia, CR Fisher, T Barnes, MN Mabila, R Wilf, ... Proceedings of the National Academy of Sciences 115 (22), E4990-E4999, 2018 | 57 | 2018 |
| An inactivated Rabies virus–based Ebola Vaccine, FILORAB1, adjuvanted with glucopyranosyl lipid A in stable emulsion confers complete protection in nonhuman primate challenge … RF Johnson, D Kurup, KR Hagen, C Fisher, R Keshwara, A Papaneri, ... The Journal of infectious diseases 214 (suppl_3), S342-S354, 2016 | 45 | 2016 |
| New developments in rabies vaccination. CR Fisher, MJ Schnell Revue scientifique et technique (International Office of Epizootics) 37 (2 …, 2018 | 23 | 2018 |
| Tetravalent rabies-vectored Filovirus and Lassa fever vaccine induces long-term immunity in nonhuman primates D Kurup, CR Fisher, G Scher, C Yankowski, AM Testa, R Keshwara, ... The Journal of infectious diseases 224 (6), 995-1004, 2021 | 15 | 2021 |
| Lyssavirus vaccine with a chimeric glycoprotein protects across phylogroups CR Fisher, DE Lowe, TG Smith, Y Yang, CL Hutson, C Wirblich, ... Cell reports 32 (3), 2020 | 15 | 2020 |
| Inactivated rabies virus–based Ebola vaccine preserved by vaporization is heat-stable and immunogenic against Ebola and protects against rabies challenge D Kurup, CR Fisher, TG Smith, T Abreu-Mota, Y Yang, FR Jackson, ... The Journal of infectious diseases 220 (9), 1521-1528, 2019 | 15 | 2019 |
| A High-Throughput, High-Containment Human Primary Epithelial Airway Organ-on-Chip Platform for SARS-CoV-2 Therapeutic Screening CR Fisher, F Mba Medie, RJ Luu, RB Gaibler, TJ Mulhern, CR Miller, ... Cells 12 (22), 2639, 2023 | 3 | 2023 |
| SARS-CoV-2 viral replication in a high throughput human primary epithelial airway organ model CR Fisher, FM Medie, RJ Luu, R Gaibler, CR Miller, TJ Mulhern, ... bioRxiv, 2021.06. 15.448611, 2021 | 3 | 2021 |
| Predicting clinical outcomes of SARS-CoV-2 drug treatments with a high throughput human airway on chip platform CR Fisher, FM Medie, RJ Luu, LL Quezada, RB Gaibler, TJ Mulhern, ... bioRxiv, 2022.06. 07.495101, 2022 | 1 | 2022 |
| A human primary airway microphysiological system infected with SARS-CoV-2 distinguishes the treatment efficacy between nirmatrelvir and repurposed compounds fluvoxamine and … LL Quezada, FM Medie, EP Gabriel, RJ Luu, LD Rubio, TJ Mulhern, ... | | 2023 |
| A human primary airway microphysiological system infected with SARS-CoV-2 distinguishes the treatment efficacy between nirmatrelvir and repurposed compounds fluvoxamine and … L Lopez Quezada, F Mba Medie, EP Gabriel, RJ Luu, LD Rubio, ... bioRxiv, 2023.06. 27.546790, 2023 | | 2023 |
| Predicting clinical outcomes of SARS-CoV-2 drug treatments with a high throughput human airway on chip platform (preprint) CR Fisher, FM Medie, RJ Luu, LL Quezada, RB Gaibler, TJ Mulhern, ... | | 2022 |
| SARS-CoV-2 Viral Replication in a High Throughput Human Primary Epithelial Airway Organ Model (preprint) CR Fisher, FM Medie, RJ Luu, R Gaibler, CR Miller, TJ Mulhern, ... | | 2021 |
| Development and Characterization of a Broadly Protective Lyssavirus Vaccine CR Fisher Thomas Jefferson University, 2020 | | 2020 |
| Glucose transporter 4 antibodies, methods of making the same, and uses thereof DF Tucker, KA Mattia, CR Fisher, BJ Doranz, JB Rucker WO Patent App. WO2019213024A1, 2019 | | 2019 |
| Composition and administration of chimeric glycoprotein lyssavirus vaccines for coverage against rabies M Schnell, CR Fisher, C Wirblich, G Tan WO Patent App. WO2018231974A1, 2018 | | 2018 |
